Impact of Non-Invasive Gene Expression Testing to Rule Out Melanoma

LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc., a molecular genomics company pioneering precision dermatology, announces the publication of a new clinical study, confirming the clinical utility of the pigmented lesion assay (PLA) in the early detection of melanoma. The PLA is a breakthrough, non-invasive test that uses molecular gene expression to identify malignant changes in a skin sample collected with adhesive patches. With a demonstrated negative predictive value of 99%, the PLA signifi